PAN explores rising Medicare Part D premiums in Pharmaceutical Commerce
Information about this website: Following the March 2026 merger of Patient Advocate Foundation and the PAN Foundation, this website is now a part of Patient Advocate Foundation and remains active during our website transition.
Where to find information during our transition:
- About the merged organization: uniting.patientadvocate.org
- Financial assistance: totalassist.org
- Additional direct patient services and resources: patientadvocate.org
- Education: panfoundation.org and education.patientadvocate.org
- Clinical trials education: clinicaltrials.panfoundation.org
- Advocacy: npaf.org
- Research: patientinsightinstitute.org
An increase in Part D plan premiums of double digits has been reported by some Medicare beneficiaries. In fact, a recent national poll from the PAN Foundation’s Cetner for Patient Research found that nearly one in three (28 percent) Medicare beneficiaries enrolled in Part D plans said the cost of the monthly premium for their prescription drug plan is higher in 2024 than it was in 2023.
In this article for Pharmaceutical Commerce, PAN Foundation Chief Mission Officer Amy Niles, outlines potential reasons for these increased premiums and what can be done to stabilize premium growth. She highlights how the Medicare Part D reforms going into effect in 2025 and the increased financial burden on Part D plans may have unintended consequences for patients when it comes to premium costs.